Brief: NextCure Initiates Phase 1/2 Clinical Trial Of NC762 For Solid Tumors
06/07/2021 21:12
July 6 (Reuters) - NextCure Inc NXTC.O :
* NEXTCURE INITIATES PHASE 1/2 CLINICAL TRIAL OF NC762 FOR
SOLID
TUMORS
* NEXTCURE INC - LOOK FORWARD TO REPORTING INITIAL DATA FROM
PHASE
1/2 CLINICAL TRIAL IN MID-2022
Source text for Eikon: ID:nGNX2FlTb6
Further company coverage: NXTC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NextCure
See all newsBrief: Xcellon Biologics Co Acquires Gmp Manufacturing Facility From Nextcure
NextCure Inc reports results for the quarter ended June 30 - Earnings Summary
NextCure Q2 net loss narrows on lower expenses
Brief: NextCure Q2 Net Income USD -14.892 Million
NextCure Inc expected to post a loss of $1.93 a share - Earnings Preview